Regulation of TFEB and V-ATPases by mTORC1.

mTOR signaling in growth control and disease. Cell (2012) 29.21

A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03

BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97

The role of autophagy in neurodegenerative disease. Nat Med (2013) 4.46

The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal (2012) 3.40

TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33

Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol (2013) 3.13

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11

MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy (2012) 2.87

Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 2.66

Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med (2012) 2.38

The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol (2012) 1.93

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84

Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat Immunol (2012) 1.83

Innate host defense requires TFEB-mediated transcription of cytoprotective and antimicrobial genes. Immunity (2014) 1.81

State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58

Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J Biol Chem (2013) 1.48

Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. J Cell Biol (2013) 1.43

ZKSCAN3 is a master transcriptional repressor of autophagy. Mol Cell (2013) 1.40

Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem (2013) 1.35

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33

A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev (2013) 1.15

Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci (2014) 1.14

Lysosomal-mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/βA3/A1-crystallin via V-ATPase-MTORC1 signaling. Autophagy (2014) 1.08

Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and lysosomal disease. EMBO Mol Med (2013) 1.04

Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest (2012) 1.04

Disrupted autophagy after spinal cord injury is associated with ER stress and neuronal cell death. Cell Death Dis (2015) 1.01

Status of mTOR activity may phenotypically differentiate senescence and quiescence. Mol Cells (2012) 1.00

Enhancing astrocytic lysosome biogenesis facilitates Aβ clearance and attenuates amyloid plaque pathogenesis. J Neurosci (2014) 1.00

MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5. J Cell Biol (2015) 0.99

Transcriptional and epigenetic regulation of autophagy in aging. Autophagy (2015) 0.97

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol (2014) 0.97

Lysosomal basification and decreased autophagic flux in oxidatively stressed trabecular meshwork cells: implications for glaucoma pathogenesis. Autophagy (2013) 0.96

Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. Hum Mol Genet (2013) 0.94

Cobalt protoporphyrin accelerates TFEB activation and lysosome reformation during LPS-induced septic insults in the rat heart. PLoS One (2013) 0.94

Recent Insights into the Structure, Regulation, and Function of the V-ATPases. Trends Biochem Sci (2015) 0.93

Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis. J Neurosci (2015) 0.93

Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy (2015) 0.91

Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis (2014) 0.91

TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy. Cell Cycle (2011) 0.90

A subunit of eukaryotic translation initiation factor 2α-phosphatase (CreP/PPP1R15B) regulates membrane traffic. J Biol Chem (2012) 0.90

ATP6V0C knockdown in neuroblastoma cells alters autophagy-lysosome pathway function and metabolism of proteins that accumulate in neurodegenerative disease. PLoS One (2014) 0.90

Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb Perspect Biol (2014) 0.90

Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. Nat Protoc (2013) 0.89

Beyond indigestion: emerging roles for lysosome-based signaling in human disease. Curr Opin Cell Biol (2015) 0.89

Function and Mechanisms of Autophagy in Brain and Spinal Cord Trauma. Antioxid Redox Signal (2015) 0.88

Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell (2014) 0.88

Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases. Ann N Y Acad Sci (2016) 0.87

Regulation of lysosome biogenesis and functions in osteoclasts. Cell Cycle (2013) 0.87

The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective. Trends Neurosci (2016) 0.87

Advances and New Concepts in Alcohol-Induced Organelle Stress, Unfolded Protein Responses and Organ Damage. Biomolecules (2015) 0.86

TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J (2015) 0.86

Autophagy and the (Pro)renin Receptor. Front Endocrinol (Lausanne) (2013) 0.85

MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation. Mol Cell Biol (2013) 0.85

The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum Mol Genet (2013) 0.83

βA3/A1-crystallin: more than a lens protein. Prog Retin Eye Res (2014) 0.83

Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and TORC1. J Cell Sci (2015) 0.82

Reprogramming of lysosomal gene expression by interleukin-4 and Stat6. BMC Genomics (2013) 0.82

Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J Neurochem (2015) 0.82

The lysosome as a command-and-control center for cellular metabolism. J Cell Biol (2016) 0.81

Elucidation of how cancer cells avoid acidosis through comparative transcriptomic data analysis. PLoS One (2013) 0.81

Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res Rev (2016) 0.80

Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology (2016) 0.80

A nanobuffer reporter library for fine-scale imaging and perturbation of endocytic organelles. Nat Commun (2015) 0.80

CRYβA3/A1-Crystallin Knockout Develops Nuclear Cataract and Causes Impaired Lysosomal Cargo Clearance and Calpain Activation. PLoS One (2016) 0.80

Modification of autophagy-lysosomal pathway as a neuroprotective treatment for spinal cord injury. Neural Regen Res (2015) 0.80

Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun (2015) 0.80

Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum. Br J Pharmacol (2012) 0.79

Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Sci Rep (2015) 0.79

Sanfilippo syndrome: causes, consequences, and treatments. Appl Clin Genet (2015) 0.79

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects. Int J Mol Sci (2016) 0.78

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2014) 0.78

Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models. PeerJ (2015) 0.78

Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1. Mol Cell Biol (2013) 0.78

An Evolutionarily Conserved PLC-PKD-TFEB Pathway for Host Defense. Cell Rep (2016) 0.78

A way to invade: a story of ErbB2 and lysosomes. Cell Cycle (2012) 0.78

Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nat Commun (2016) 0.77

Attenuation of the phosphatidylinositol 3-kinase/Akt signaling pathway by Porphyromonas gingivalis gingipains RgpA, RgpB, and Kgp. J Biol Chem (2015) 0.77

"Get the Balance Right": Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders. J Neuromuscul Dis (2016) 0.76

Lipolysis and lipophagy in lipid storage myopathies. Biochim Biophys Acta (2016) 0.76

Oncogenic H-Ras up-regulates acid β-hexosaminidase by a mechanism dependent on the autophagy regulator TFEB. PLoS One (2014) 0.76

The Function of V-ATPases in Cancer. Physiol Rev (2016) 0.76

mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol (2017) 0.76

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget (2017) 0.75

TFEBulous control of traffic by mTOR. EMBO J (2011) 0.75

Regulation of ULK1 expression and autophagy by STAT1. J Biol Chem (2016) 0.75

Autophagy dysregulation in Danon disease. Cell Death Dis (2017) 0.75

Inhibition of Ral GTPases Using a Stapled Peptide Approach. J Biol Chem (2016) 0.75

Knockdown of GSK3β increases basal autophagy and AMPK signalling in nutrient-laden human aortic endothelial cells. Biosci Rep (2016) 0.75

Curcumin targets the TFEB-lysosome pathway for induction of autophagy. Oncotarget (2016) 0.75

Degradation and beyond: the macrophage lysosome as a nexus for nutrient sensing and processing in atherosclerosis. Curr Opin Lipidol (2015) 0.75

Transcription factor EB: a central regulator of both the autophagosome and lysosome. Hepatology (2012) 0.75

Identification of modulators of autophagic flux in an image-based high content siRNA screen. Autophagy (2016) 0.75

Global deletion of BCATm increases expression of skeletal muscle genes associated with protein turnover. Physiol Genomics (2015) 0.75

Unique epigenetic gene profiles define human breast cancers with poor prognosis. Oncotarget (2016) 0.75

Multistep regulation of TFEB by MTORC1. Autophagy (2017) 0.75

Transcription Factor EB Is Selectively Reduced in the Nuclear Fractions of Alzheimer's and Amyotrophic Lateral Sclerosis Brains. Neurosci J (2016) 0.75

TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits. eNeuro (2016) 0.75

Investigation of endosome and lysosome biology by ultra pH-sensitive nanoprobes. Adv Drug Deliv Rev (2016) 0.75

The crucial impact of lysosomes in aging and longevity. Ageing Res Rev (2016) 0.75

TOR signaling in growth and metabolism. Cell (2006) 35.29

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83

AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72

Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 14.51

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08

Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet (2009) 14.06

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50

Autophagy and the integrated stress response. Mol Cell (2010) 11.21

A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A (2008) 10.07

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev (2003) 9.58

Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92

TFEB links autophagy to lysosomal biogenesis. Science (2011) 8.87

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25

Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92

The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75

Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51

A gene network regulating lysosomal biogenesis and function. Science (2009) 7.17

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet (2002) 7.12

Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03

Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol (2007) 6.86

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab (2008) 6.60

Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol (2007) 6.48

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol (2003) 6.32

Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature (2010) 6.26

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73

Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature (2005) 5.30

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00

Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol (2011) 4.96

Integration of oxygen signaling at the consensus HRE. Sci STKE (2005) 4.95

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev (2008) 4.52

The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer (2008) 4.42

The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem (2005) 4.34

Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell (2006) 4.20

TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13

PEComas: the past, the present and the future. Virchows Arch (2007) 3.93

Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet (2004) 3.78

Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab (2008) 3.03

Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97

Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A (2009) 2.95

Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal (2009) 2.92

The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J Exp Biol (2006) 2.72

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem (2003) 2.66

Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science (2011) 2.58

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol (2002) 2.46

The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Curr Opin Cell Biol (2008) 2.44

The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem (1997) 2.42

TOR coordinates bulk and targeted endocytosis in the Drosophila melanogaster fat body to regulate cell growth. J Cell Biol (2006) 2.24

Uncommon and recently described renal carcinomas. Mod Pathol (2009) 2.13

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet (2003) 2.09

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol (2007) 1.99

Regulation of the small GTPase Rheb by amino acids. Oncogene (2006) 1.85

The late endosome is essential for mTORC1 signaling. Mol Biol Cell (2010) 1.79

Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol (2006) 1.76

Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73

Regulation of mTORC1 by the Rab and Arf GTPases. J Biol Chem (2010) 1.60

Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets (2008) 1.52

Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet (2003) 1.47

Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. Proc Natl Acad Sci U S A (2011) 1.43

Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem (2001) 1.23

Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res (2006) 1.16

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol (2009) 1.15

Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene (2011) 1.10

Hypoxic regulation of Id-1 and activation of the unfolded protein response are aberrant in neuroblastoma. J Biol Chem (2006) 1.10

Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry (2010) 1.04

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol (2011) 0.95

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol (2007) 5.05

BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97

Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70

Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol (2011) 3.12

Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol (2008) 3.02

Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83

The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol (2011) 2.72

RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (2003) 2.62

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol (2009) 2.36

Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34

Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med (2007) 2.06

Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat Chem Biol (2005) 2.00

Rz/Rz1 lysis gene equivalents in phages of Gram-negative hosts. J Mol Biol (2007) 1.87

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84

Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat Immunol (2012) 1.83

Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75

Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res (2010) 1.74

Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72

Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72

Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression. Mol Endocrinol (2006) 1.71

Information flow analysis of interactome networks. PLoS Comput Biol (2009) 1.68

Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging (2004) 1.65

State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58

Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett (2004) 1.57

A gender gap in the dermatology literature? Cross-sectional analysis of manuscript authorship trends in dermatology journals during 3 decades. J Am Acad Dermatol (2009) 1.55

Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res (2002) 1.52

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry (2010) 1.50

TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50

Prolapse follow-up at 5 years or more: myth or reality? Urology (2011) 1.48

Recognition of chromosomal DNA by PNAs. Chem Biol (2004) 1.41

Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry (2002) 1.40

A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res (2007) 1.39

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer (2013) 1.36

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol (2010) 1.36

SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33

Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA. Biochemistry (2007) 1.33

Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res (2011) 1.26

Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini. Nat Chem Biol (2010) 1.25

Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res (2013) 1.24

Extending recognition by peptide nucleic acids (PNAs): binding to duplex DNA and inhibition of transcription by tail-clamp PNA-peptide conjugates. Biochemistry (2003) 1.20

Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res (2010) 1.20

Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol (2010) 1.20

Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. Nucleic Acids Res (2012) 1.20

Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry (2002) 1.19

DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.19

Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. Proc Natl Acad Sci U S A (2006) 1.16

Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs. Health Serv Res (2008) 1.16

PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One (2010) 1.15

Translating research into practice intervention improves management of acute pain in older hip fracture patients. Health Serv Res (2009) 1.13

Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell (2011) 1.12

Challenges for RNAi in vivo. Trends Biotechnol (2004) 1.11

Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. Nucleic Acid Ther (2012) 1.10

Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res (2011) 1.10

Bayesian optimal discovery procedure for simultaneous significance testing. BMC Bioinformatics (2009) 1.10

Predicting potential miRNA target sites within gene promoters. Bioorg Med Chem Lett (2009) 1.10

Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol (2010) 1.10

Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. Nat Protoc (2006) 1.08

Allele-selective inhibition of trinucleotide repeat genes. Drug Discov Today (2012) 1.08

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A (2011) 1.07

RNA sequencing: platform selection, experimental design, and data interpretation. Nucleic Acid Ther (2012) 1.07

Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res (2011) 1.06

Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. Biochemistry (2004) 1.05

Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci (2009) 1.05

Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol (2011) 1.04

Clinical status of duplex RNA. Bioorg Med Chem Lett (2010) 1.04

Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry (2010) 1.04

Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res (2013) 1.04

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res (2009) 1.04

Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet (2009) 1.03

Impact of routine cavity shave margins on breast cancer re-excision rates. Ann Surg Oncol (2010) 1.03

Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol Chem (2011) 1.03

Ultrastructural uncoupling between T-tubules and sarcoplasmic reticulum in human heart failure. Cardiovasc Res (2013) 1.03

The N-terminal transmembrane domain of lambda S is required for holin but not antiholin function. J Bacteriol (2009) 1.02

Multipotent capacity of immortalized human bronchial epithelial cells. PLoS One (2011) 1.01

RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res (2008) 1.01

Oral health, nutrient intake and dietary quality in the very old. J Am Dent Assoc (2002) 1.01

Acute pain treatment for older adults hospitalized with hip fracture: current nursing practices and perceived barriers. Appl Nurs Res (2003) 1.01

A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A (2010) 1.01